Serina Therapeutics Inc
SER2.650USD
-0.007-0.26%
收盤 12/19, 16:00（美東）報價延遲15分鐘
27.94M總市值
虧損本益比TTM
關於 Serina Therapeutics Inc 公司
Serina Therapeutics Inc. is a clinical-stage biotechnology company developing a pipeline of wholly owned drug product candidates to treat neurological diseases and other indications. The Company's POZ Platform provides the potential to improve the integrated efficacy and safety profile of multiple modalities including small molecules, RNA-based therapeutics and antibody-based drug conjugates (ADCs). Its proprietary POZ technology is based on a synthetic, water soluble, low viscosity polymer called poly(2-oxazoline). Its POZ technology is engineered to provide greater control in drug loading and more precision in the rate of release of attached drugs delivered via subcutaneous injection. SER-252 is the Company’s lead candidate for advanced Parkinson’s disease. SER-252 is an investigational apomorphine therapy developed with its POZ platform and designed to provide continuous dopaminergic stimulation.
Serina Therapeutics Inc簡介
公司代碼SER
公司名稱Serina Therapeutics Inc
上市日期Nov 29, 2018
CEOLedger (Steven)
員工數量12
證券類型Ordinary Share
年結日Nov 29
公司地址601 Genome Way,
城市HUNTSVILLE
上市交易所NASDAQ OMX – NASDAQ Basic Amex
國家United States of America
郵編35806
電話12563279630
網址https://serinatherapeutics.com/
公司代碼SER
上市日期Nov 29, 2018
CEOLedger (Steven)
Serina Therapeutics Inc公司高管
名稱
名稱/職務
職務
持股
持股變動
Dr. Gregory Hugh (Greg) Bailey, M.D.
Dr. Gregory Hugh (Greg) Bailey, M.D.
Independent Director
Independent Director
67.24K
--
Dr. Srini Tenjarla, Ph.D.
Dr. Srini Tenjarla, Ph.D.
Senior Vice President - CMC and Formulation
Senior Vice President - CMC and Formulation
--
--
Mr. Gregory S. (Greg) Curhan
Mr. Gregory S. (Greg) Curhan
Chief Financial Officer
Chief Financial Officer
--
--
Dr. Stephen (Steve) Brannan, M.D.
Dr. Stephen (Steve) Brannan, M.D.
Independent Director
Independent Director
--
--
Dr. Balkrishan (Simba) Gill, Ph.D.
Dr. Balkrishan (Simba) Gill, Ph.D.
Executive Chairman of the Board
Executive Chairman of the Board
--
--
Mr. Steven Ledger
Mr. Steven Ledger
Chief Executive Officer, Director
Chief Executive Officer, Director
--
--
Dr. Randall W. Moreadith, M.D., Ph.D.
Dr. Randall W. Moreadith, M.D., Ph.D.
Chief Development Officer
Chief Development Officer
--
--
Dr. Jay R. Venkatesan, M.D.
Dr. Jay R. Venkatesan, M.D.
Independent Director
Independent Director
--
--
Mr. Richard Marshall, M.D., Ph.D.
Mr. Richard Marshall, M.D., Ph.D.
Independent Director
Independent Director
--
--
Ms. Karen J. Wilson, CPA
Ms. Karen J. Wilson, CPA
Independent Director
Independent Director
--
--
名稱
名稱/職務
職務
持股
持股變動
Dr. Gregory Hugh (Greg) Bailey, M.D.
Dr. Gregory Hugh (Greg) Bailey, M.D.
Independent Director
Independent Director
67.24K
--
Dr. Srini Tenjarla, Ph.D.
Dr. Srini Tenjarla, Ph.D.
Senior Vice President - CMC and Formulation
Senior Vice President - CMC and Formulation
--
--
Mr. Gregory S. (Greg) Curhan
Mr. Gregory S. (Greg) Curhan
Chief Financial Officer
Chief Financial Officer
--
--
Dr. Stephen (Steve) Brannan, M.D.
Dr. Stephen (Steve) Brannan, M.D.
Independent Director
Independent Director
--
--
Dr. Balkrishan (Simba) Gill, Ph.D.
Dr. Balkrishan (Simba) Gill, Ph.D.
Executive Chairman of the Board
Executive Chairman of the Board
--
--
Mr. Steven Ledger
Mr. Steven Ledger
Chief Executive Officer, Director
Chief Executive Officer, Director
--
--
收入明細
FY2025Q2
FY2025Q1
FY2024
FY2023
FY2022
FY2021
FY2020
FY2019
FY2018
由於公司未披露，未能獲取相關數據
地區USD
名稱
營收
佔比
United States
130.00K
0.00%
業務
地區
由於公司未披露，未能獲取相關數據
股東統計
更新時間: 11月15日 週六
更新時間: 11月15日 週六
持股股東
股東類型
持股股東
持股股東
佔比
Juvenescence Ltd
30.64%
Puffinus L.P.
8.49%
McMillan (Helen w)
6.64%
The Vanguard Group, Inc.
1.69%
Ledger (Steven A)
0.90%
其他
51.65%
持股股東
持股股東
佔比
Juvenescence Ltd
30.64%
Puffinus L.P.
8.49%
McMillan (Helen w)
6.64%
The Vanguard Group, Inc.
1.69%
Ledger (Steven A)
0.90%
其他
51.65%
股東類型
持股股東
佔比
Corporation
39.12%
Individual Investor
8.18%
Investment Advisor
3.01%
Hedge Fund
0.78%
Investment Advisor/Hedge Fund
0.54%
Research Firm
0.02%
其他
48.35%
機構持股
更新時間: 10月1日 週三
更新時間: 10月1日 週三
報告期間
機構數
持股數
持股佔比
持股變動
2025Q3
56
464.13K
4.40%
+21.47K
2025Q2
59
6.70M
67.24%
+256.13K
2025Q1
61
6.74M
67.68%
+273.42K
2024Q4
60
6.52M
69.43%
+1.01M
2024Q3
60
5.48M
62.28%
+460.95K
2024Q2
62
5.34M
60.76%
+463.56K
2024Q1
62
4.83M
57.65%
+2.79M
2023Q4
55
610.31K
56.56%
+2.00K
2023Q3
59
606.40K
56.20%
-1.31K
2023Q2
62
604.05K
55.98%
-7.36K
查看更多
股東持股明細
名稱
持股數
佔比
持股變動
變動比例
公告日期
Juvenescence Ltd
3.27M
31%
--
--
Sep 17, 2025
Puffinus L.P.
904.88K
8.59%
--
--
Sep 17, 2025
McMillan (Helen w)
708.61K
6.72%
-133.79K
-15.88%
Sep 17, 2025
The Vanguard Group, Inc.
150.62K
1.43%
+85.29K
+130.55%
Jun 30, 2025
Ledger (Steven A)
95.73K
0.91%
-227.93K
-70.42%
Sep 17, 2025
Broadwood Capital, Inc.
85.22K
0.81%
--
--
Jun 30, 2025
Waverly Advisors, LLC
67.49K
0.64%
--
--
Jun 30, 2025
Bailey (Gregory Hugh)
67.24K
0.64%
--
--
Sep 17, 2025
Geode Capital Management, L.L.C.
28.88K
0.27%
-322.00
-1.10%
Jun 30, 2025
查看更多
持股ETF
更新時間: 12月6日 週六
更新時間: 12月6日 週六
機構名稱
佔比
iShares Micro-Cap ETF
0%
iShares Core S&P Total U.S. Stock Market ETF
0%
iShares Micro-Cap ETF
佔比0%
iShares Core S&P Total U.S. Stock Market ETF
佔比0%
分紅派息
近5年累計派現
0.00
美元
公告日期
分紅計劃
股權登記日
現金發放日
除權除息日
暫無數據
拆合股
公告日期
類型
比率
Mar 07, 2024
Merger
35.17→1
Mar 07, 2024
Merger
35.17→1
Mar 07, 2024
Merger
35.17→1
Mar 07, 2024
Merger
35.17→1
公告日期
類型
比率
Mar 07, 2024
Merger
35.17→1
Mar 07, 2024
Merger
35.17→1
Mar 07, 2024
Merger
35.17→1
Mar 07, 2024
Merger
35.17→1
常見問題
Serina Therapeutics Inc的前五大股東是誰？
Serina Therapeutics Inc的前五大股東如下：
Juvenescence Ltd持有股份：3.27M佔總股份比例：31.00%。
Puffinus L.P.持有股份：904.88K佔總股份比例：8.59%。
McMillan (Helen w)持有股份：708.61K佔總股份比例：6.72%。
The Vanguard Group, Inc.持有股份：150.62K佔總股份比例：1.43%。
Ledger (Steven A)持有股份：95.73K佔總股份比例：0.91%。
Juvenescence Ltd持有股份：3.27M佔總股份比例：31.00%。
Puffinus L.P.持有股份：904.88K佔總股份比例：8.59%。
McMillan (Helen w)持有股份：708.61K佔總股份比例：6.72%。
The Vanguard Group, Inc.持有股份：150.62K佔總股份比例：1.43%。
Ledger (Steven A)持有股份：95.73K佔總股份比例：0.91%。
Serina Therapeutics Inc的前三大股東類型是什麼？
Serina Therapeutics Inc 的前三大股東類型分別是：
Juvenescence Ltd
Puffinus L.P.
McMillan (Helen w)
Juvenescence Ltd
Puffinus L.P.
McMillan (Helen w)
有多少機構持有Serina Therapeutics Inc(SER)的股份？
截至2025Q3，共有56家機構持有Serina Therapeutics Inc的股份，合計持有的股份價值約為464.13K，占公司總股份的4.40% 。與2025Q2相比，機構持股有所增加，增幅為-62.84%。
哪個業務部門對Serina Therapeutics Inc的收入貢獻最大？
在FY2025Q2，--業務部門對Serina Therapeutics Inc的收入貢獻最大，創收--，占總收入的--% 。
